Dr. Serge Dauphin, MD

Dr. Dauphin practices at Arnot Ogden Medical Center in Elmira, New York, part of Centralus Health.

Dr. Dauphin's NPI, 1609824648, was assigned on May 4, 2006. Dr. Dauphin holds New York license 186155.

Dr. Dauphin's primary practice is Arnot Ogden Medical Center, at 600 Roe Avenue, Elmira, NY 14905 in Chemung County. The practice phone is (607) 737-4100.

Dr. Dauphin's primary practice is Arnot Ogden Medical Center in Elmira, New York, part of Centralus Health. Dr. Dauphin is also affiliated with Strong Memorial Hospital. The medical group on file is Arnot Ogden Medical Center. Dmand AI also links Dr. Dauphin to 3 more hospitals and 1 medical group, each named with a free account. Dr. Dauphin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dauphin practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dauphin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Dauphin's licenses on file in 2 states: New York and Pennsylvania.

CMS data shows 567 Medicare services from Dr. Dauphin across 4 procedure codes in 2024, all of them office visits, for 257 Medicare patients. Medicare paid $43,595 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 257 Medicare patients who saw Dr. Dauphin in 2024. The largest group is 65 to 74, with 96 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dauphin's median patient age at 71, with 60% women.

In 2024, Dr. Dauphin wrote 1,084 Medicare Part D claims for 224 patients. 75% of them were for generic drugs. CMS names the drug for 840 of them, across 25 drugs with 11 or more claims each, at $3,408,573 in total drug cost. In 2023, CMS named 623 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Dauphin for performance year 2024, reported as part of a group. Dr. Dauphin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dauphin as offering telehealth.

Dmand AI links 2 papers to Dr. Dauphin, published from 2023 to 2024. The most frequent topics are Cancer Survivors. Dr. Dauphin's most frequent co-authors are Makiko Ban-Hoefen, MD, Allison Marian Magnuson, DO and Supriya Gupta Mohile, MD.

Dmand AI links Dr. Dauphin to 10 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Brain Neoplasms. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 69 general payments to Dr. Dauphin from 17 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 52% of the total. Bristol-Myers Squibb Company paid the most, $309.